Class IB phosphatidylinositol 3-kinase p110gamma (PI3Kgamma) has gained increasing attention as a promising drug target for the treatment of inflammatory disease. Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up potentially huge opportunities for these drugs. Several companies have been pursuing small-molecule PI3Kgamma inhibitor projects, but none of them has progressed to the clinic yet. Here, we discuss the insights gained so far and the main challenges that are emerging on the path to developing PI3Kgamma inhibitors for the treatment of human disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrd2145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of PI3 Kinases in Cell Signaling and Soleus Muscle Atrophy During Three Days of Unloading.
Int J Mol Sci
January 2025
Myology Laboratory, Institute of Biomedical Problems (IBP), RAS, 123007 Moscow, Russia.
During skeletal muscle unloading, phosphoinositide 3-kinase (PI3K), and especially PI3K gamma (PI3Kγ), can be activated by changes in membrane potential. Activated IP3 can increase the ability of Ca to enter the nucleus through IP3 receptors. This may contribute to the activation of transcription factors that initiate muscle atrophy processes.
View Article and Find Full Text PDFInduction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control.
Gut
January 2025
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
Background: The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical studies have implicated macrophage-mediated immune tolerance. Hence, pathways that regulate macrophage phenotype are of strategic interest, with reprogramming strategies focusing on inhibitors of phosphoinositide 3-kinase-gamma (PI3Kγ) due to restricted immune cell expression. Inhibition of PI3Kγ alone is ineffective in PDAC, despite increased infiltration of CD8+ T cells.
View Article and Find Full Text PDFEvaluating the Anti-inflammatory Potential of JN-KI3: The Therapeutic Role of PI3Kγ-Selective Inhibitors in Asthma Treatment.
Inflammation
January 2025
Department of Clinical Research Center for Wuxi No.2 People's Hospital, Jiangnan University Medical Center, Wuxi, 214000, Jiangsu, China.
Asthma is a chronic airway inflammatory disease of the airways characterized by the involvement of numerous inflammatory cells and factors. Therefore, targeting airway inflammation is one of the crucial strategies for developing novel drugs in the treatment of asthma. Phosphoinositide 3-kinase gamma (PI3Kγ) has been demonstrated to have a significant impact on inflammation and immune responses, thus emerging as a promising therapeutic target for airway inflammatory disease, including asthma.
View Article and Find Full Text PDFMVGNet: Prediction of PI3K Inhibitors Using Multitask Learning and Multiview Frameworks.
ACS Omega
November 2024
Zhejiang Province Key Laboratory of Smart Management & Application of Modern Agricultural Re-sources, School of Information Engineering, Huzhou University, Huzhou 313000, Zhejiang Province,China.
Article Synopsis
- PI3K is an important intracellular enzyme made up of regulatory (p85) and catalytic (p110) subunits, existing in four different isoforms important for cancer treatment.
- The study introduces MVGNet, a deep learning framework that improves the prediction of how well molecules can inhibit these PI3K isoforms by using multitask learning techniques.
- MVGNet outperforms traditional machine learning and deep learning models, achieving impressive accuracy metrics (AUC-ROC and AUC-PR), and helps further understand the relationship between the structure of PI3K inhibitors and their activity.
The Importance of Phosphoinositide 3-Kinase in Neuroinflammation.
Int J Mol Sci
October 2024
NeuroAllergy Research Laboratory (NARL), School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, 75 Pigdons Road, Geelong, VIC 3216, Australia.
Neuroinflammation, characterised by the activation of immune cells in the central nervous system (CNS), plays a dual role in both protecting against and contributing to the progression of neurodegenerative diseases, such as Alzheimer's disease (AD) and multiple sclerosis (MS). This review explores the role of phosphoinositide 3-kinase (PI3K), a key enzyme involved in cellular survival, proliferation, and inflammatory responses, within the context of neuroinflammation. Two PI3K isoforms of interest, PI3Kγ and PI3Kδ, are specific to the regulation of CNS cells, such as microglia, astrocytes, neurons, and oligodendrocytes, influencing pathways, such as Akt, mTOR, and NF-κB, that control cytokine production, immune cell activation, and neuroprotection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!